A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

BACKGROUND: The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Asakawa, Jumpei, Iguchi, Taro, Tamada, Satoshi, Yasuda, Sayaka, Ninomiya, Noriko, Kato, Minoru, Yamasaki, Takeshi, Ohmachi, Tetusji, Nakatani, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://www.ncbi.nlm.nih.gov/pubmed/30026950
http://dx.doi.org/10.1186/s12610-018-0074-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://www.ncbi.nlm.nih.gov/pubmed/30026950
http://dx.doi.org/10.1186/s12610-018-0074-2

Ejemplares similares